Non-invasive imaging of atherosclerosis regression with magnetic resonance to guide drug development

Paolo Raggi, Damiano Baldassarre, Simon Day, Eric De Groot, Z A Fayad

Research output: Contribution to journalArticle

Abstract

Slowing of progression and inducing the regression of atherosclerosis with medical therapy have been shown to be associated with an extensive reduction in risk of cardiovascular events. This proof of concept was obtained with invasive angiographic studies but these are, for obvious reasons, impractical for sequential investigations. Non-invasive imaging has henceforth replaced the more cumbersome invasive studies and has proven extremely valuable in numerous occasions. Because of excellent reproducibility and no radiation exposure, magnetic resonance imaging (MRI) has become the non-invasive method of choice to assess the efficacy of anti-atherosclerotic drugs. The high accuracy of this technology is particularly helpful in rare diseases where the small number of affected patients makes the conduct of outcome-trials in large cohorts impractical. With MRI it is possible to assess the extent, as well as the composition, of atherosclerotic plaques and this further enhances the utility of this technology.

Original languageEnglish
Pages (from-to)476-82
Number of pages7
JournalAtherosclerosis
Volume251
DOIs
Publication statusPublished - Aug 2016

Fingerprint

Atherosclerosis
Magnetic Resonance Spectroscopy
Magnetic Resonance Imaging
Technology
Atherosclerotic Plaques
Risk Reduction Behavior
Rare Diseases
Pharmaceutical Preparations
Therapeutics
Radiation Exposure

Keywords

  • Journal Article
  • Review

Cite this

Non-invasive imaging of atherosclerosis regression with magnetic resonance to guide drug development. / Raggi, Paolo; Baldassarre, Damiano; Day, Simon; De Groot, Eric; Fayad, Z A.

In: Atherosclerosis, Vol. 251, 08.2016, p. 476-82.

Research output: Contribution to journalArticle

Raggi, Paolo ; Baldassarre, Damiano ; Day, Simon ; De Groot, Eric ; Fayad, Z A. / Non-invasive imaging of atherosclerosis regression with magnetic resonance to guide drug development. In: Atherosclerosis. 2016 ; Vol. 251. pp. 476-82.
@article{edbf43298f49464bb791a838beb29959,
title = "Non-invasive imaging of atherosclerosis regression with magnetic resonance to guide drug development",
abstract = "Slowing of progression and inducing the regression of atherosclerosis with medical therapy have been shown to be associated with an extensive reduction in risk of cardiovascular events. This proof of concept was obtained with invasive angiographic studies but these are, for obvious reasons, impractical for sequential investigations. Non-invasive imaging has henceforth replaced the more cumbersome invasive studies and has proven extremely valuable in numerous occasions. Because of excellent reproducibility and no radiation exposure, magnetic resonance imaging (MRI) has become the non-invasive method of choice to assess the efficacy of anti-atherosclerotic drugs. The high accuracy of this technology is particularly helpful in rare diseases where the small number of affected patients makes the conduct of outcome-trials in large cohorts impractical. With MRI it is possible to assess the extent, as well as the composition, of atherosclerotic plaques and this further enhances the utility of this technology.",
keywords = "Journal Article, Review",
author = "Paolo Raggi and Damiano Baldassarre and Simon Day and {De Groot}, Eric and Fayad, {Z A}",
note = "Copyright {\circledC} 2016 Elsevier Ireland Ltd. All rights reserved.",
year = "2016",
month = "8",
doi = "10.1016/j.atherosclerosis.2016.06.028",
language = "English",
volume = "251",
pages = "476--82",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Non-invasive imaging of atherosclerosis regression with magnetic resonance to guide drug development

AU - Raggi, Paolo

AU - Baldassarre, Damiano

AU - Day, Simon

AU - De Groot, Eric

AU - Fayad, Z A

N1 - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

PY - 2016/8

Y1 - 2016/8

N2 - Slowing of progression and inducing the regression of atherosclerosis with medical therapy have been shown to be associated with an extensive reduction in risk of cardiovascular events. This proof of concept was obtained with invasive angiographic studies but these are, for obvious reasons, impractical for sequential investigations. Non-invasive imaging has henceforth replaced the more cumbersome invasive studies and has proven extremely valuable in numerous occasions. Because of excellent reproducibility and no radiation exposure, magnetic resonance imaging (MRI) has become the non-invasive method of choice to assess the efficacy of anti-atherosclerotic drugs. The high accuracy of this technology is particularly helpful in rare diseases where the small number of affected patients makes the conduct of outcome-trials in large cohorts impractical. With MRI it is possible to assess the extent, as well as the composition, of atherosclerotic plaques and this further enhances the utility of this technology.

AB - Slowing of progression and inducing the regression of atherosclerosis with medical therapy have been shown to be associated with an extensive reduction in risk of cardiovascular events. This proof of concept was obtained with invasive angiographic studies but these are, for obvious reasons, impractical for sequential investigations. Non-invasive imaging has henceforth replaced the more cumbersome invasive studies and has proven extremely valuable in numerous occasions. Because of excellent reproducibility and no radiation exposure, magnetic resonance imaging (MRI) has become the non-invasive method of choice to assess the efficacy of anti-atherosclerotic drugs. The high accuracy of this technology is particularly helpful in rare diseases where the small number of affected patients makes the conduct of outcome-trials in large cohorts impractical. With MRI it is possible to assess the extent, as well as the composition, of atherosclerotic plaques and this further enhances the utility of this technology.

KW - Journal Article

KW - Review

U2 - 10.1016/j.atherosclerosis.2016.06.028

DO - 10.1016/j.atherosclerosis.2016.06.028

M3 - Article

C2 - 27341753

VL - 251

SP - 476

EP - 482

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -